<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1409-0015</journal-id>
<journal-title><![CDATA[Medicina Legal de Costa Rica]]></journal-title>
<abbrev-journal-title><![CDATA[Med. leg. Costa Rica]]></abbrev-journal-title>
<issn>1409-0015</issn>
<publisher>
<publisher-name><![CDATA[Asociación Costarricense de Medicina Forense]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1409-00152017000200082</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Los triglicéridos y la aterogénesis]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Carvajal Carvajal]]></surname>
<given-names><![CDATA[Carlos]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital de Guápiles Laboratorio Clínico ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2017</year>
</pub-date>
<volume>34</volume>
<numero>2</numero>
<fpage>82</fpage>
<lpage>89</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_arttext&amp;pid=S1409-00152017000200082&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_abstract&amp;pid=S1409-00152017000200082&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_pdf&amp;pid=S1409-00152017000200082&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen Las lipoproteínas ricas en triglicéridos (TRL) comprenden los quilomicrones, las VLDL y sus remanentes. Las TRL son altamente heterogéneas, difiriendo en el tamaño, densidad, composición y riesgo cardiovascular asociado. La evidencia acumulada demuestra una fuerte correlación entre el riesgo de enfermedad cardiovascular (ECV) y el nivel de TAG en ayunas y no en ayunas (posprandial). Se han propuesto dos mecanismos por los cuales las TRL pueden incrementar la ateroesclerosis: los remanentes de TRL y las VLDL son capaces de penetrar la íntima arterial, pueden ser internalizados por los macrófagos y convertirlos en células espumosas. Segundo: durante la lipólisis de las TRL se liberan un número de lípidos inflamatorios que alteran la biología del endotelio. Los TAG no son directamente aterogénicos, pero representan un importante biomarcador de ECV a causa de su asociación con una alta concentración de partículas pequeñas y densas de LDL, niveles reducidos de colesterol HDL y con apo C-III, una proteína proinflamatoria y proaterogénica.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Triglyceride-rich lipoproteins (TRL) comprise chylomicrons, VLDL and their remnants. TRL are highly heterogeneous, differing in size, density, composition, and associated cardiovascular risk. Accumulating evidence demonstrates a strong correlation between the risk of cardiovascular disease (CVD) and both non-fasting (postprandial) and fasting plasma TAG level. Two mechanisms by which TRL might increase atherosclerosis are proposed: TRL remnants and VLDL are able to penetrate the arterial intima, can be internalized by macrophages and convert these cells into foam cells. Second: during lipolysis of TRL a number of inflammatory lipids are released that alter endothelial biology. TAG are not directly atherogenic but represent an important biomarker of CVD because of their association with a high concentration of small dense LDL particles, reduced HDL cholesterol levels, and with apo C-III, a proinflammatory and proatherogenic protein.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Triglicéridos]]></kwd>
<kwd lng="es"><![CDATA[aterosclerosis]]></kwd>
<kwd lng="es"><![CDATA[lipoproteínas ricas en triglicéridos]]></kwd>
<kwd lng="es"><![CDATA[dislipidemia]]></kwd>
<kwd lng="es"><![CDATA[apo C-III]]></kwd>
<kwd lng="en"><![CDATA[Triglycerides]]></kwd>
<kwd lng="en"><![CDATA[atherosclerosis]]></kwd>
<kwd lng="en"><![CDATA[triglyceride-rich lipoprotein]]></kwd>
<kwd lng="en"><![CDATA[dyslipidemia]]></kwd>
<kwd lng="en"><![CDATA[apo C-III]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bornfeldt]]></surname>
<given-names><![CDATA[k.]]></given-names>
</name>
<name>
<surname><![CDATA[Tabas]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Insulin resistance, hyperglycemia and atherosclerosis]]></article-title>
<source><![CDATA[Cell Metab]]></source>
<year>2011</year>
<volume>14</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>575-85</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Millán]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Pintó]]></surname>
<given-names><![CDATA[X.]]></given-names>
</name>
<name>
<surname><![CDATA[Muñoz]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Zúñiga]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Rubiés-Prat]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Pallardo]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lipoprotein ratios: physiological significance and clinical usefulness in cardiovascular Prevention]]></article-title>
<source><![CDATA[Vasc Health Risk Prevent]]></source>
<year>2009</year>
<volume>5</volume>
<page-range>757-65</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Toth]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease.]]></article-title>
<source><![CDATA[Vascular Health and Risk Management]]></source>
<year>2016</year>
<volume>12</volume>
<page-range>171-83</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mascarenhas-Melo]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Palabra]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Marado]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Sereno]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Texeira-Lemos]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Freitas]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Emergent biomarkers of residual cardiovascular risk in patients with low HDL-c and/or high triglycerides and average LDL-c concentrations: focus on HDL subpopulations, oxidized LDL, adiponectin, and uric acid]]></article-title>
<source><![CDATA[The Scientific World J]]></source>
<year>2013</year>
<page-range>1-16</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Fisher]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lipoprotein metabolism, dyslipidemia and nonalcoholic fatty liver disease]]></article-title>
<source><![CDATA[Sem Liver Dis]]></source>
<year>2013</year>
<volume>33</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>380-8</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Díaz]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Liem]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Utilidad de la medición de la apolipoproteína B en la práctica clínica]]></article-title>
<source><![CDATA[Clin Invest Arterioscl]]></source>
<year>2005</year>
<volume>7</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>142-6</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chapman]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Ginsberg]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Amarenco]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Andreotti]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Borén]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Catapano]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guiadance for management]]></article-title>
<source><![CDATA[European Heart J]]></source>
<year>2011</year>
<volume>32</volume>
<page-range>1345-61</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Ginsberg]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Increased Very Low Density Lipoprotein secretion, hepatic steatosis, and insulin resistance]]></article-title>
<source><![CDATA[Trends Endocrinol Metab]]></source>
<year>2011</year>
<volume>22</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>353-63</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Klop]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Willem]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Castro-Cabezas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dyslipidemia in obesity: mechanisms and potential targets]]></article-title>
<source><![CDATA[Nutrients]]></source>
<year>2013</year>
<volume>5</volume>
<page-range>1218-40</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Welty]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[How do elevated triglycerides and low HDL-cholesterol affect inflammation and atherothrombosis?]]></article-title>
<source><![CDATA[Curr Cardiol Rep]]></source>
<year>2013</year>
<volume>15</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>378-400</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vergés]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pathophysiology of diabetic dyslipidaemia: where are we?]]></article-title>
<source><![CDATA[Diabetología]]></source>
<year>2015</year>
<volume>58</volume>
<page-range>886-99</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Daniels]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Killinger]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Michal]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Wright]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Jiang]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lipoproteins, cholesterol homeostasis and cardiac health]]></article-title>
<source><![CDATA[Int J Biol Sciences]]></source>
<year>2009</year>
<volume>5</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>474-88</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nakajima]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Nakano]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Tokita]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Nagamine]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Inazu]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Kobayashi]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Postprandial lipoproteína metabolism; VLDL vs chylomicrons]]></article-title>
<source><![CDATA[Clin Chem Acta]]></source>
<year>2011</year>
<volume>412</volume>
<numero>15-16</numero>
<issue>15-16</issue>
<page-range>1306-18</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Enkhmaa]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Ozturk]]></surname>
<given-names><![CDATA[Z.]]></given-names>
</name>
<name>
<surname><![CDATA[Anuurad]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Berglund]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Postprandial lipoproteins and cardiovascular disease risk in diabetes mellitus]]></article-title>
<source><![CDATA[Curr Diab Rep]]></source>
<year>2010</year>
<volume>10</volume>
<page-range>61-9</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carey]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[Bishop]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Laranjo]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Harshfield]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Kwiat]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Sacks]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Controbution of high plasma triglycerides and low High-Density Lipoprotein cholesterol to residual risk of coronary heart disease after establishment of Low- Density Lipoprotein cholesterol control]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2010</year>
<volume>106</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>757-63</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wan]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Q.]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[X.]]></given-names>
</name>
<name>
<surname><![CDATA[Zeng]]></surname>
<given-names><![CDATA[Z.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The association between Triglyceride/High Density Lipoprotein cholesterol ratio and all-cause mortality in acute coronary syndrome after coronary revascularization]]></article-title>
<source><![CDATA[PLoS ONE]]></source>
<year>2015</year>
<volume>10</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1-11</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Talayero]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Sacks]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The role of triglycerides in atherosclerosis]]></article-title>
<source><![CDATA[Curr Cardiol Rep]]></source>
<year>2011</year>
<volume>13</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>544-52</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bitzur]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Kamari]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Shaish]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Harats]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Triglycerides an HDL cholesterol]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2009</year>
<volume>32</volume>
<numero>^s2</numero>
<issue>^s2</issue>
<supplement>2</supplement>
<page-range>S373-7</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kannel]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
<name>
<surname><![CDATA[Vasan]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Triglycerides as vascular risk factors: new epidemiologic insights for current opinion in cardiology]]></article-title>
<source><![CDATA[Curr Opin Cardiol]]></source>
<year>2009</year>
<volume>24</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>345-50</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Luo]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Peng]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The emerging role of apolipoprotein C-III: beyond effects on triglyceride metabolism]]></article-title>
<source><![CDATA[Lipids in Health and Disease]]></source>
<year>2016</year>
<volume>15</volume>
<page-range>1-7</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Han]]></surname>
<given-names><![CDATA[S. H.]]></given-names>
</name>
<name>
<surname><![CDATA[Nicholls]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Sakuma]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Koh]]></surname>
<given-names><![CDATA[K. K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hipertriglyceridemia and cardiovascular diseases: revisited]]></article-title>
<source><![CDATA[Korean Circulation J]]></source>
<year>2016</year>
<volume>46</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>135-44</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[katsanos]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical considerations and mechanistic Determinants of posprandial lipemia in older adults]]></article-title>
<source><![CDATA[Adv Nutrition]]></source>
<year>2014</year>
<volume>5</volume>
<page-range>226-34</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dallinga-Thie]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Kroon]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Borén]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Chapman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Triglyceride-rich lipoproteins and remnants: targets for therapy]]></article-title>
<source><![CDATA[Curr Cardiol Rep]]></source>
<year>2016</year>
<volume>18</volume>
<page-range>1-9</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Golberg]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Eckel]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[McPherson]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Triglycerides and heart disease, still a hypothesis?]]></article-title>
<source><![CDATA[Arterioscler Thromb Vasc Biol]]></source>
<year>2011</year>
<volume>31</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1716-25</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Boren]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Matikainen]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Adiels]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Taskinen]]></surname>
<given-names><![CDATA[M. R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Postprandial hypertriglyceridemia as a coronary risk factor]]></article-title>
<source><![CDATA[Clin Chim Acta]]></source>
<year>2014</year>
<volume>431</volume>
<page-range>31-42</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rapp]]></surname>
<given-names><![CDATA[J. H.]]></given-names>
</name>
<name>
<surname><![CDATA[Lespine]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Hamilton]]></surname>
<given-names><![CDATA[R. L.]]></given-names>
</name>
<name>
<surname><![CDATA[Colyvas]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Chaumeton]]></surname>
<given-names><![CDATA[A. H.]]></given-names>
</name>
<name>
<surname><![CDATA[Tweedie-Hardman]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Triglyceriderich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque]]></article-title>
<source><![CDATA[Arterioscler Thromb Vasc Biol]]></source>
<year>1994</year>
<volume>14</volume>
<page-range>1767-74</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Daugherty]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Lange]]></surname>
<given-names><![CDATA[L. G.]]></given-names>
</name>
<name>
<surname><![CDATA[Sobel]]></surname>
<given-names><![CDATA[B. E.]]></given-names>
</name>
<name>
<surname><![CDATA[Schonfeld]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aortic accumulation and plasma clearance of b-VLDL and HDL: effects of diet-induced hypercholesterolemia in rabbits]]></article-title>
<source><![CDATA[J Lipid Res]]></source>
<year>1985</year>
<volume>26</volume>
<page-range>955-63</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Proctor]]></surname>
<given-names><![CDATA[S. D.]]></given-names>
</name>
<name>
<surname><![CDATA[Mamo]]></surname>
<given-names><![CDATA[J. C. L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Retention of fluorescent-labelled chylomicron remnants within the intima of the arterial wall-evidence that plaque cholesterol may be derived from post-prandial lipoproteins]]></article-title>
<source><![CDATA[Eur J Clin Invest]]></source>
<year>1998</year>
<volume>28</volume>
<page-range>497-504</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Gill]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Pedersen]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Higgins]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Newman]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Rutledge]]></surname>
<given-names><![CDATA[J. C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Triglyceride-rich lipprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation]]></article-title>
<source><![CDATA[J Lipid Research]]></source>
<year>2009</year>
<volume>50</volume>
<page-range>204-13</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hartigh]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Altman]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Norman]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Rutledge]]></surname>
<given-names><![CDATA[J. C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Posprandial VLDL lipolysis products increase monocyte adhesion and lipid droplet formation via activation of ERK2 and NFkB]]></article-title>
<source><![CDATA[Am J Physiol Heart Circ Physiol]]></source>
<year>2013</year>
<volume>306</volume>
<page-range>H109-20</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Qamar]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Khetarpal]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Khera]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Qasim]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Rader]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Reilly]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Plasma Apo C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics]]></article-title>
<source><![CDATA[Arterioscler Thromb Vasc Biol]]></source>
<year>2015</year>
<volume>35</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1880-8</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sacks]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The crucial roles of Apolipoproteins E and C-III in ApoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia]]></article-title>
<source><![CDATA[Curr Opin Lipidol]]></source>
<year>2015</year>
<volume>26</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>56-63</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zheng]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Khoo]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Furtado]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Sacks]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Apolipoprotein Hypertriglyceridemia and the dense Low-Density Lipoprotein phenotype]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2010</year>
<volume>121</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1722-34</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gordts]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Nock]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Son]]></surname>
<given-names><![CDATA[N. H.]]></given-names>
</name>
<name>
<surname><![CDATA[Ramms]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Lew]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Gonzales]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors]]></article-title>
<source><![CDATA[J Clin Invest]]></source>
<year>2016</year>
<volume>126</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>2855-66</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tran-Dinh]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Diallo]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Delbosc]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Varela-Pérez]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Dang]]></surname>
<given-names><![CDATA[Q. B.]]></given-names>
</name>
<name>
<surname><![CDATA[Lapergue]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[HDL and endothelial Protection]]></article-title>
<source><![CDATA[British J Pharmacology]]></source>
<year>2013</year>
<volume>169</volume>
<page-range>493-511</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Norata]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Catapano]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Molecular mechanisms responsible for the antiinflammatory and protective effect of HDL on the endothelium]]></article-title>
<source><![CDATA[Vasc Health and Risk Management]]></source>
<year>2005</year>
<volume>1</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>119-29</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yuhanna]]></surname>
<given-names><![CDATA[I. S.]]></given-names>
</name>
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[B. E.]]></given-names>
</name>
<name>
<surname><![CDATA[Cox]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Hahner]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Osborne-Lawrence]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[Y. L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase]]></article-title>
<source><![CDATA[Nat Med]]></source>
<year>2001</year>
<volume>7</volume>
<page-range>853-7</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Athyros]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[Tziomalos]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Karangiannis]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Mikhailidis]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment]]></article-title>
<source><![CDATA[Open Cardiovasc Med J]]></source>
<year>2011</year>
<volume>5</volume>
<page-range>24-34</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shinkai]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cholesterol ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases]]></article-title>
<source><![CDATA[Vascular health and risk management]]></source>
<year>2012</year>
<volume>8</volume>
<page-range>323-31</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jung]]></surname>
<given-names><![CDATA[U. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[M. S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, nonalcoholic fatty liver disease]]></article-title>
<source><![CDATA[Int J Mol Sci]]></source>
<year>2014</year>
<volume>15</volume>
<page-range>6184-223</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Magkos]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Mohammed]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Mittendorfer]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of obesity on the plasma lipoprotein subclass profile in normoglycemic and normolipidemic men and women]]></article-title>
<source><![CDATA[Int J Obes (Lond)]]></source>
<year>2008</year>
<volume>32</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1655-64</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Chung]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Shelness]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Parks]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hepatic ABCA1 and VLDL triglyceride production]]></article-title>
<source><![CDATA[Biochim Biophys Acta]]></source>
<year>2012</year>
<volume>1821</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>770-7</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carmena]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Duriez]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Fruchart]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atherogenic lipoprotein particles in atherosclerosis]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2004</year>
<volume>15</volume>
<page-range>III-2 - III-7</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nikolic]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Katsiki]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Montalto]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Isenovic]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Mikhailidis]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Rizzo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lipoprotein subfraction in metabolic syndrome and obesity: clinical significance and therapeutic approaches]]></article-title>
<source><![CDATA[Nutrients]]></source>
<year>2013</year>
<volume>5</volume>
<page-range>928-48</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
